Moreover, high DRP1 expression and mitochondrial fragmentation contribute to maintenance of brain tumour-initiating cells, and genetic ablation of DRP1 or its pharmacological inhibition with mDIVI1 reduces their tumorigenicity in vitro and in vivo [7]. The gene discussed is DNM1L; the disease is brain neoplasm.